Pharma Update
Alzheimer's disease: Continuing to invest in high unmet need area
Leveraging key learnings to develop next generation therapies
Clinical development program in Alzheimer's disease
Roche
Neurology Update
Roche IR Event
Oct 2023
AD program strategy
NME
MOA
Phl
Ph II
Ph III
Selecting the
right population
888
Having the right
endpoints
Bepranemab
Anti-tau mAb
Trontinemab
Anti-Aẞ mAb
Semorinemab
Anti-tau mAb
Ph Il completed
Biomarker
Ability to cross the
enabled diagnosis
blood brain barrier
0
GSM
Small molecule
Ph I completed
•
Using prior experience and key learnings to
develop effective clinical trials
Leading diagnostic solutions, including screening
and confirmatory tests, developing novel blood-
based and digital biomarker options
• Innovative Brain Shuttle technology to enable superior penetration of BBB, leading to deeper and faster
Aẞ reduction - potential for better efficacy
Investigating MoAs to target various stages of the anti-amyloid cascade with GSM acting early in the
pathological process and anti-tau mAbs acting at the end of the cascade
.
Ph I dose escalation for trontinemab and FIH data for GSM to be presented at CTAD 2023 on Oct 24-27th
AD=Alzheimer's disease; BBB-blood brain barrier; mAb-monoclonal antibody; Aẞ-Amyloid ẞ; GSM-gamma secretase modulator; FIH=first in human; MoA-Mode of action
108View entire presentation